

1 **African-specific improvement of a polygenic hazard score for age at diagnosis of**
2 **prostate cancer**

3
4 **Abstract**

5 Introduction: Polygenic hazard score (PHS) models are associated with age at diagnosis
6 of prostate cancer. Our model developed in Europeans (PHS46), showed reduced
7 performance in men with African genetic ancestry. We used a cross-validated search to
8 identify SNPs that might improve performance in this population.

9 Material and Methods: Anonymized genotypic data were obtained from the PRACTICAL
10 consortium for 6,253 men with African genetic ancestry. Ten iterations of a ten-fold
11 cross-validation search were conducted, to select SNPs that would be included in the
12 final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox
13 proportional hazards framework using age at diagnosis as the dependent variable and
14 PHS46, and selected SNPs as predictors. The performance of PHS46 and
15 PHS46+African were compared using the same cross-validated approach.

16 Results: Three SNPs (rs76229939, rs74421890, and rs5013678) were selected for
17 inclusion in PHS46+African. All three SNPs are located on chromosome 8q24.
18 PHS46+African showed substantial improvements in all performance metrics measured,
19 including a 75% increase in the relative hazard of those in the upper 20% compared to
20 the bottom 20% (2.47 to 4.34) and a 20% reduction in the relative hazard of those in the
21 bottom 20% compared to the middle 40% (0.65 to 0.53).

22 Conclusions: We identified three SNPs that substantially improved the association of
23 PHS46 with age at diagnosis of prostate cancer in men with African genetic ancestry to
24 levels comparable to Europeans and Asians. A strategy of building on established
25 statistical models might benefit ancestral groups generally under-represented in
26 genome-wide association studies.

1 Introduction

2 Polygenic models can provide personalized estimates of the risk of developing
3 prostate cancer. In the context of survival analysis, these models can provide insight into
4 age at diagnosis of prostate cancer, and thus could be used to guide decisions on
5 whether and when to offer screening¹. Studies of polygenic models have often included
6 only individuals of European genetic ancestry, owing to greater availability of data from
7 that population^{2,3}. As a consequence, these models have been tailored to identify and
8 estimate coefficients of genetic common variants for that particular population, while
9 potentially missing variants that may hold value in other populations². There is concern
10 that using these European-focused models could actually exacerbate health disparities²⁻
11 ⁴.

12 As an example, our group recently published on the performance of a polygenic
13 hazard score (PHS) originally developed using a European dataset, in a multi-ethnic
14 dataset consisting of individuals of European, African, and Asian genetic ancestry⁵. The
15 model (called here PHS46), includes 46 single nucleotide polymorphisms (SNPs) in its
16 calculation and was strongly associated with age at diagnosis in all three genetic
17 populations ($p < 10^{-16}$). However, the hazard ratio for prostate cancer between individuals
18 in the upper 20th percentile to those in the lower 20th percentile of PHS46 was
19 approximately half as large for those with African genetic ancestry (2.6) as it was for
20 those with European (5.6) or Asian (4.6) ancestry. A similar pattern was observed for
21 clinically significant prostate cancer and for death from prostate cancer.

22 In the current study, we attempt to bridge the apparent gap in model performance
23 of PHS46 for individuals with African genetic ancestry. To this end, we used a machine
24 learning approach to systematically search for SNPs that add statistical value to a base
25 model of PHS46 among African men (PHS46+African). By including PHS46 as a

1 covariate in our SNP search, we sought to identify those SNPs that may hold particular
2 value for individuals with African genetic ancestry.

3

4 **Material and Methods**

5 Study dataset

6 We obtained genotype and phenotype data from the Prostate Cancer Association
7 Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)⁶
8 consortium for this study. Genotyping was performed using the OncoArray platform⁶ and
9 had undergone quality assurance steps, as described previously⁷. The genotypic
10 ancestry of each individual was also determined previously^{6,8}. In total, the African
11 dataset consisted of data from 6,253 men with African genotypic ancestry. Missing SNP
12 calls were replaced with the mean of the genotyped data for that SNP in the African
13 dataset. Individuals without prostate cancer were censored at age at last follow-up in the
14 Cox proportional hazards models. All contributing studies were approved by the relevant
15 ethics committees; written informed consent was obtained from the study participants⁹.
16 The present analyses used de-identified data from the PRACTICAL consortium. Please
17 refer to Table S1 for a description of the PRACTICAL study groups that contributed data
18 towards this analysis. PHS46 risk score for each individual in the African dataset was
19 estimated as the sum of SNP allele counts (X) multiplied by their respective coefficients
20 (β)⁵:

$$21 \quad PHS46 = \sum_{i=1}^{46} X_i \beta_i$$

22

23 SNP-scan

24 Training and testing sets were generated using 10 iterations of a 10-fold cross-
25 validation structure resulting in 100 total permutations. For each permutation, a

1 multivariable logistic regression model using case/control status as the dependent
2 variable was estimated using each genotyped SNP in turn, adjusting for PHS46 and four
3 principal components based on genetic ancestry, determined previously⁸. SNPs with p-
4 values less than 1×10^{-6} were considered for further analysis. In order of increasing p-
5 value, each SNP was tested in a multiple Cox proportional hazards model, after
6 adjusting for PHS46, four ancestral principal components, and previously selected
7 SNPs. The Cox model in the SNP-scan used age at diagnosis of prostate cancer as the
8 dependent variable. If the p-value of the coefficient of the tested SNP was less than
9 1×10^{-6} , it was considered for the final model in that permutation. SNPs that reached this
10 p-value threshold in more than 50% of the permutations were selected to construct the
11 PHS46+African model, consisting of PHS46 and the newly identified SNPs.

12

13 Comparing performance between PHS46 and PHS46+African

14 For each permutation of the previously described cross-validation structure, an
15 PHS46+African Cox proportional hazards model was estimated in the training set using
16 PHS46 and the selected SNPs as independent predictors. The PHS46+African risk
17 score for each individual is then estimated using the corresponding PHS46 score,
18 selected SNP allele counts (Y) and their respective coefficients (α):

$$19 \quad PHS46 + African = PHS46 + \sum_{j=1}^{SNPs} Y_j \alpha_j$$

20 The performance of the PHS46+African and PHS46 models was then determined in the
21 cross-validation testing set, and the resulting hazard ratios (HR) were obtained, as
22 previously described¹. For each model, the PHS risk scores within the cross-validation
23 testing set are assigned to quantile groups identified using the corresponding training set
24 control values. The hazard ratio between two quantile groups, such as those in the top
25 20% to those in the bottom 20%, is estimated as the exponential of the difference in

1 mean PHS values for each group. In this calculation, the PHS values are linearly scaled
2 by a sample-weight correction factor, to account for case-control sampling^{1,5,10}. Three
3 HR were calculated: HR80/20 (top 20% to bottom 20%), HR98/50 (top 2% to middle
4 40%) and HR20/50 (bottom 20% to middle 40%). The average HR across permutations
5 for both PHS46+African and PHS46 are reported.

6 To allow for comparisons with previously published results, the performance
7 metrics for PHS46 and PHS46+African were also estimated for age at diagnosis of
8 clinically significant prostate cancer. When estimating performance for clinically
9 significant prostate cancer, controls and non-clinically significant cancers were censored
10 at age of last follow-up and age of diagnosis, respectively. The previously used criteria
11 for clinically significant cancer were any of: Gleason score ≥ 7 , stage T3-T4, PSA
12 concentration ≥ 10 ng/mL, nodal metastasis, or distant metastasis¹. Paired t-tests were
13 used to test for statistical significant differences ($\alpha = 0.05$) in HR between
14 PHS46+African and PHS46.

15 Additionally, in each permutation, the performance of a Cox model consisting of
16 PHS46 and SNPs that were considered in that permutation was also estimated. These
17 results are provided within the Table S2 and provide performance estimates that are not
18 prone to information leakage from training to testing set.

19

20 Characterization of PHS+African

21 Coefficients of the PHS46+African model, consisting of PHS46 and the SNPs
22 selected in the SNP-scan, were estimated using 1000 bootstrapped samples of the
23 African dataset.

24

25 **Results**

26 Individual and OncoArray characteristics

1 In total, there were 3,013 men with (cases) and 3,240 men without (controls)
2 prostate cancer in the African dataset. The mean [95% CI] ages of cases and controls
3 were 62.4 [62.1, 62.7] and 61.8 [61.4, 62.1] years respectively. The OncoArray
4 genotypic data, after the quality assurance process, included 444,323 SNPs.

5

6 Single Nucleotide Polymorphism (SNP)-scan

7 Across the 100 permutations of the cross-validation iterations, a total of twelve
8 SNPs were considered for final selection (Table S3). Three SNPs were selected in more
9 than 50% of the permutations and included in the final PHS46+African model. By cross-
10 referencing the chromosomal positions against dbSNP¹¹, these variants were identified
11 as rs76229939, rs74421890, and rs5013678. All 3 SNPs (Table 1) are located on
12 chromosome 8q24, a region of the chromosome previously identified as containing
13 common variants associated with prostate cancer^{12,13}. An examination of the Pearson
14 correlation coefficients (Table S4) showed little correlation, ranging from -0.05 to -0.07,
15 among genotype data from the 3 SNPs in the African dataset.

16 Reference threshold (Table S5) and mean (Table S6) values for PHS46+African
17 in the African dataset are presented in the Supplemental Data.

18

19 Performance of PHS46+African

20 Figure 1 demonstrates the difference in HRs between PHS46+African and
21 PHS46 within the African dataset using age at diagnosis of any prostate cancer. Overall,
22 we observed an improvement in all the metrics calculated: a 75% increase in HR98/50
23 from 2.10 to 3.67; a 79% increase in HR80/20 from 2.47 to 4.42; and a 23% decrease in
24 HR20/50 from 0.65 to 0.51. We also observed improvements in all performance metrics
25 when using age at diagnosis of clinically significant prostate cancer: 103% increase in
26 HR98/50 from 1.91 to 3.88, 113% improvement in HR80/20 from 2.21 to 4.71, and 29%

1 improvement in HR20/50 from 0.70 to 0.50. All observed changes in HR were
2 statistically significant ($p < 1 \times 10^{-16}$).

3

4 **Discussion**

5 Using a cross-validated search of a dataset made up entirely of men with African
6 genetic ancestry, we were able to identify three SNPs that substantially improved the
7 performance of PHS46 in this population to levels that are comparable to those
8 observed in Europeans and Asians. The three SNPs, rs76229939, rs74421890, and
9 rs5013678, are all located on chromosome 8q24 – a region of the genome where
10 variants have been associated with prostate cancer in both the general population and
11 specifically in men with African genetic ancestry^{13,14}. Despite the relative proximity of the
12 three SNPs on chromosome 8, their genetic data was not strongly correlated in our
13 dataset, suggesting that each SNP provides non-redundant information for an
14 individual's genetic score.

15 Each of the three SNPs have been previously identified in the literature to be
16 associated with prostate cancer: rs76229939 is an intron variant of the prostate-cancer-
17 associated transcript 2 (PCAT2) gene, while rs74421890 and rs5013678 are both non-
18 coding transcript variants of the prostate-cancer-associated non-coding RNA 1
19 (PRNCR1) gene. The minor allele frequencies of rs76229939 and rs74421890 in
20 Europeans, as reported by dbSNP¹¹, are approximately zero to three decimal places,
21 which may explain why they were not selected in the original formulation of PHS46.

22 This study is not meant to be an exhaustive search for all possible SNPs that are
23 associated with the age of diagnosis of prostate cancer in individuals with African
24 genetic ancestry. Our study is also limited by the small number of available observations
25 relative to those often found in many genome-wide association studies, which can have
26 tens or hundreds of thousands of individuals. However, we were able to extract

1 information that is likely robust by employing a cross-validated search for those SNPs
2 that specifically add value to the performance of PHS46, and not simply independently
3 associated with prostate cancer. We also note that no SNP score, including PHS46 and
4 PHS46+African, has been shown to discriminate men at risk of aggressive prostate
5 cancer from those at risk of indolent prostate cancer. Finally, the performance metrics
6 reported in this study may be biased by the leakage of information across cross-
7 validated folds of the data when identifying those SNPs to include in the final African-
8 PHS model. This bias is expected to be similar for all SNPs and should not have
9 influenced selection of the three SNPs included in the final model over those not
10 selected.

11 In conclusion, we identified three SNPs (rs76229939, rs74421890, and
12 rs5013678) that substantially improved the performance of PHS46 in a dataset of men
13 with African genetic ancestry. We believe that this strategy of building on established
14 models developed on large dataset could be applied to other groups that are generally
15 under-represented in genome-wide association studies. This strategy may further help to
16 bridge performance gaps in personalized genetic risk scores across populations.

17

1 **References**

- 2 1. Seibert, T.M., Fan, C.C., Wang, Y., Zuber, V., Karunamuni, R., Parsons, J.K., Eeles,
3 R.A., Easton, D.F., Kote-Jarai, Z., Al Olama, A.A., et al. (2018). Polygenic hazard score
4 to guide screening for aggressive prostate cancer: Development and validation in large
5 scale cohorts. *BMJ* 360, 1–7.
- 6 2. Duncan, L., Shen, H., Gelaye, B., Meijssen, J., Ressler, K., Feldman, M., Peterson, R.,
7 and Domingue, B. (2019). Analysis of polygenic risk score usage and performance in
8 diverse human populations. *Nat. Commun.* 10,.
- 9 3. Popejoy, A., and Fullerton, S. (2016). Genomics is falling on diversity. *Nature* 538,.
- 10 4. Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019).
11 Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat.*
12 *Genet.* 51, 584–591.
- 13 5. Minh-Phuong, H.-L., Chieh Fan, C., Karunamuni, R., Martinez, M.E., Eeles, R.A.,
14 Kote-Jarai, Z., Muir, K., Collaborators, U., Schleutker, J., Pashayan, N., et al. (2019).
15 Polygenic hazard score predicts aggressive and fatal prostate cancer in multi-ethnic
16 populations. *MedRxiv*.
- 17 6. Amos, C.I., Dennis, J., Wang, Z., Byun, J., Schumacher, F.R., Gayther, S.A., Casey,
18 G., Hunter, D.J., Sellers, T.A., Gruber, S.B., et al. (2017). The oncoarray consortium: A
19 network for understanding the genetic architecture of common cancers. *Cancer*
20 *Epidemiol. Biomarkers Prev.* 26, 126–135.
- 21 7. Leitzmann, M.F., and Rohrmann, S. (2012). Risk factors for the onset of prostatic
22 cancer: Age, location, and behavioral correlates. *Clin. Epidemiol.* 4, 1–11.
- 23 8. Li, Y., Byun, J., Cai, G., Xiao, X., Han, Y., Cornelis, O., Dinulos, J.E., Dennis, J.,
24 Easton, D., Gorlov, I., et al. (2016). FastPop: A rapid principal component derived
25 method to infer intercontinental ancestry using genetic data. *BMC Bioinformatics* 17, 1–
26 8.

- 1 9. Kote-Jarai, Z., Easton, D.F., Stanford, J.L., Ostrander, E.A., Schleutker, J., Ingles,
2 S.A., Schaid, D., Thibodeau, S., Dörk, T., Neal, D., et al. (2008). Multiple novel prostate
3 cancer predisposition loci confirmed by an international study: The PRACTICAL
4 consortium. *Cancer Epidemiol. Biomarkers Prev.* 17, 2052–2061.
- 5 10. Therneau, T.M., and Li, H. (1999). Computing the Cox Model for Case Cohort
6 Designs. *Lifetime Data Anal.* 5, 99–112.
- 7 11. Sherry, S.T., Ward, M., and Sirotkin, K. (1999). dbSNP - database for single
8 nucleotide polymorphisms and other classes of minor genetic variation. *Genome Res.* 9,
9 677–679.
- 10 12. Yeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P., Wacholder, S., Minichiello,
11 M.J., Fearnhead, P., Yu, K., Chatterjee, N., et al. (2007). Genome-wide association
12 study of prostate cancer identifies a second risk locus at 8q24. *Nat. Genet.* 39, 645–649.
- 13 13. Haiman, C.A., Patterson, N., Freedman, M.L., Myers, S.R., Pike, M.C., Waliszewska,
14 A., Neubauer, J., Tandon, A., Schirmer, C., McDonald, G.J., et al. (2007). Multiple
15 regions within 8q24 independently affect risk for prostate cancer. *Nat. Genet.* 39, 638–
16 644.
- 17 14. Han, Y., Rand, K.A., Hazelett, D.J., Ingles, S.A., Kittles, R.A., Strom, S.S., Rybicki,
18 B.A., Nemesure, B., Isaacs, W.B., Stanford, J.L., et al. (2016). Prostate cancer
19 susceptibility in men of African ancestry at 8q24. *J. Natl. Cancer Inst.* 108, 1–5.
- 20
21

1 **Figure Legends**

2 **Figure 1. Comparison between PHS46 and PHS46+African.** Mean hazard ratio

3 metrics plotted for PHS46 and PHS46+African models in the African dataset.

4 Improvements were observed in all performance metrics investigated. Error bars

5 represent 95% confidence interval.

6

1 **Table 1. Characteristics of PHS46+African SNPs.** RS-ID, chromosome and base-pair
2 position (based on version 37), effect and reference alleles, bootstrap-estimated beta,
3 and effect allele frequencies in Africans from 1000Genomes (referenced from dbSNP) of
4 the three SNPs selected for addition to PHS46.

RS number	Chromosome	Position	Effect	Ref	beta	Frequency (%)
rs76229939	8	128085394	G	A	0.441	4.8
rs74421890	8	128096183	A	G	0.415	4.1
rs5013678	8	128103979	G	A	-0.260	8.1

5

6

- 1 **Supplemental Data Description**
- 2 The Supplemental Data contains (1) six tables
- 3

1 **Appendix A1. Data Availability Statement**

2 The data used in this work were obtained from the Prostate Cancer Association Group to
3 Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium,
4 Readers who are interested in accessing the data must first submit a proposal to the
5 Data Access Committee. If the reader is not a member of the consortium, their concept
6 form must be sponsored by a principal investigator (PI) of one of the PRACTICAL
7 consortium member studies. If approved by the Data Access Committee, PIs within the
8 consortium, each of whom retains ownership of their data submitted to the consortium,
9 can then choose to participate in the specific proposal. In addition, portions of the data
10 are available for request from dbGaP (database of Genotypes and Phenotypes) which is
11 maintained by the National Center for Biotechnology Information (NCBI):

12 <https://www.ncbi.nlm.nih.gov/gap/?term=lcogs+prostate>[https://www.ncbi.nlm.nih.gov/gap](https://www.ncbi.nlm.nih.gov/gap/?term=lcogs+prostate)
13 [/?term=lcogs+prostate](https://www.ncbi.nlm.nih.gov/gap/?term=lcogs+prostate).

14 Anyone can apply to join the consortium. The eligibility requirements are listed here:
15 http://practical.icr.ac.uk/blog/?page_id=9. Joining the consortium would not guarantee
16 access, as a proposal for access would still be submitted to the Data Access Committee,
17 but there would be no need for a separate member sponsor. Readers may find
18 information about application by using the contact information below:

19

20 Rosalind Eeles

21 Principal Investigator for PRACTICAL

22 Professor of Oncogenetics

23 Institute of Cancer Research (ICR)

24 Sutton, UK

25 Email: PRACTICAL@icr.ac.uk

26 URL: <http://practical.icr.ac.uk>

27 Tel: ++44 (0)20 8722 4094

28

1 **Appendix A2. Funding sources for the PRACTICAL consortium**

2

3 CRUK and PRACTICAL consortium

4 This work was supported by the Canadian Institutes of Health Research, European
5 Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-
6 F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118,
7 C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National
8 Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA
9 148537-01 (the GAME-ON initiative).

10 We would also like to thank the following for funding support: The Institute of Cancer
11 Research and The Everyman Campaign, The Prostate Cancer Research Foundation,
12 Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal,
13 The National Cancer Research Network UK, The National Cancer Research Institute
14 (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical
15 Research Centre at The Institute of Cancer Research and The Royal Marsden NHS
16 Foundation Trust.

17 The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant
18 support from The National Health and Medical Research Council, Australia (126402,
19 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394,
20 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of
21 Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall's. EAO,
22 DMK, and EMK acknowledge the Intramural Program of the National Human Genome
23 Research Institute for their support.

24 Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH)
25 [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility
26 (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research
27 (CIDR) under contract number HHSN268201200008].

28 This study would not have been possible without the contributions of the following:
29 Coordination team, bioinformatician and genotyping centers: Genotyping at CCGE,
30 Cambridge: Caroline Baines and Don Conroy

31

1 Funding for the iCOGS infrastructure came from: the European Community's Seventh
2 Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175)
3 (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174,
4 C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the
5 National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19
6 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the
7 Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health
8 Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen
9 Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian
10 Cancer Research Fund.

11

12 This study would not have been possible without the contributions of the following: Per
13 Hall (COGS); Douglas F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla,
14 Qin Wang (BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton,
15 Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-
16 Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Joe
17 Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of
18 the Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira
19 and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier,
20 Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff
21 of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune
22 F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory,
23 and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer
24 and the staff of Mayo Clinic Genotyping Core Facility

25

26 Additional funding and acknowledgments from studies in PRACTICAL:

27

28 Information of the PRACTICAL consortium can be found at <http://practical.icr.ac.uk/>

29

30 BioVU

31 The dataset(s) used for the analyses described were obtained from Vanderbilt University
32 Medical Center's BioVU, which is supported by institutional funding and by the National
33 Center for Research Resources, Grant UL1 RR024975-01 (which is now at the National
34 Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06).

1

2 CPDR

3 Uniformed Services University for the Health Sciences HU0001-10-2-0002 (PI: David G.
4 McLeod, MD)

5

6 EPICAP

7 The EPICAP study was supported by grants from Ligue Nationale Contre le Cancer;
8 Institut National du Cancer (INCa); Fondation ARC; Fondation de France; Agence
9 Nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail
10 (ANSES); Ligue départementale du Val de Marne. The EPICAP study group would like
11 to thank all urologists, Antoinette Anger and Hasina Randrianasolo (study monitors),
12 Anne-Laure Astolfi, Coline Bernard, Oriane Noyer, Marie-Hélène De Campo, Sandrine
13 Margaroline, Louise N'Diaye, Sabine Perrier-Bonnet (Clinical Research nurses)

14

15 KARUPROSTATE

16 The Karuprostate study was supported by the the Frech National Health Directorate, the
17 Association pour la Recherche sur le Cancer, la Ligue Nationale contre le Cancer, the
18 French Agency for Environmental and Occupational Health Safety (ANSES) and by the
19 Association pour la Recherche sur les Tumeurs de la Prostate. We would like to thank
20 Séverine Ferdinand for valuable contributions to the study.

21

22 MOFFITT

23 The Moffitt group was supported by the US National Cancer Institute (R01CA128813, PI:
24 J.Y. Park).

25

26 NMHS

27 Funding for the Nashville Men's Health Study (NMHS) was provided by the National
28 Institutes of Health Grant numbers: RO1CA121060

29

30 PCaP

31 The North Carolina - Louisiana Prostate Cancer Project (PCaP) and the Health Care
32 Access and Prostate Cancer Treatment in North Carolina (HCaP-NC) study are carried
33 out as collaborative studies supported by the Department of Defense contract DAMD 17-

1 03-2-0052 and the American Cancer Society award RSGT-08-008-01-CPHPS,
2 respectively.

3 The authors thank the staff, advisory committees and research subjects participating in
4 the PCaP and HCaP-NC studies for their important contributions.

5

6 PROtEuS

7 PROtEuS was supported financially through grants from the Canadian Cancer Society
8 [13149, 19500, 19864, 19865] and the Cancer Research Society, in partnership with the
9 Ministère de l'enseignement supérieur, de la recherche, de la science et de la
10 technologie du Québec, and the Fonds de la recherche du Québec - Santé. PROtEuS
11 would like to thank its collaborators and research personnel, and the urologists involved
12 in subjects recruitment. We also wish to acknowledge the special contribution made by
13 Ann Hsing and Anand Chokkalingam to the conception of the genetic component of
14 PROtEuS.

15

16 SABOR

17 The SABOR research is supported by NIH/NCI Early Detection Research Network, grant
18 U01 CA0866402-18. Also supported by the Cancer Center Support Grant to the Mays
19 Cancer Center from the National Cancer Institute (US) P30 CA054174

20

21 SCCS

22 SCCS is funded by NIH grant R01 CA092447, and SCCS sample preparation was
23 conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the
24 Vanderbilt-Ingram Cancer Center (P30 CA68485). Data on SCCS cancer cases used in
25 this publication were provided by the Alabama Statewide Cancer Registry; Kentucky
26 Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer
27 Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry,
28 North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry;
29 Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer
30 Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department
31 of Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas
32 Central Cancer Registry is fully funded by a grant from National Program of Cancer
33 Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer
34 cases from Mississippi were collected by the Mississippi Cancer Registry which

1 participates in the National Program of Cancer Registries (NPCR) of the Centers for
2 Disease Control and Prevention (CDC). The contents of this publication are solely the
3 responsibility of the authors and do not necessarily represent the official views of the
4 CDC or the Mississippi Cancer Registry.

5

6 SCPCS

7 SCPCS is funded by CDC grant S1135-19/19, and SCPCS sample preparation was
8 conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the
9 Vanderbilt-Ingram Cancer Center (P30 CA68485).

10

11 SFPCS

12 SFPCS was funded by California Cancer Research Fund grant 99-00527V-10182

13 SWOG-PCPT / SWOG-SELECT

14 PCPT and SELECT are funded by Public Health Service grants U10CA37429 and
15 5UM1CA182883 from the National Cancer Institute. The authors thank the site
16 investigators and staff and, most importantly, the participants from PCPT who donated
17 their time to this trial.

18

19 UKGPCS

20 UKGPCS would also like to thank the following for funding support: The Institute of
21 Cancer Research and The Everyman Campaign, The Prostate Cancer Research
22 Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer
23 Appeal, The National Cancer Research Network UK, The National Cancer Research
24 Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical
25 Research Centre at The Institute of Cancer Research and The Royal Marsden NHS
26 Foundation Trust. UKGPCS should also like to acknowledge the NCRN nurses, data
27 managers and Consultants for their work in the UKGPCS study. UKGPCS would like to
28 thank all urologists and other persons involved in the planning, coordination, and data
29 collection of the study. KM and AL were in part supported from the NIHR Manchester
30 Biomedical Research Centre

31

32 WUGS

33 WUGS would like to thank the following for funding support: The Anthony DeNovi Fund,
34 the Donald C. McGraw Foundation, and the St. Louis Men's Group Against Cancer.

1 **Appendix A3 – Members of the PRACTICAL Consortium**

2 Christopher A. Haiman¹, Fredrick R. Schumacher^{2,3}, Sara Benlloch^{4,5}, Ali Amin Al
3 Olama^{6,7}, Sonja I. Berndt⁸, David V. Conti¹, Fredrik Wiklund⁹, Stephen Chanock⁸, Susan
4 M. Gapstur¹⁰, Victoria L. Stevens¹⁰, Jyotsna Batra^{11,12}, Judith Clements^{11,12}, APCB
5 BioResource^{13,14}, Henrik Grönberg¹⁵, Nora Pashayan^{16,17}, Johanna Schleutker^{18,19},
6 Demetrius Albanes⁸, Stephanie Weinstein⁸, Alicja Wolk^{20,21}, Catharine West²², Lorelei
7 Mucci²³, Stella Koutros⁸, Karina Dalsgaard Sørensen^{24,25}, Eli Marie Grindedal²⁶, David E.
8 Neal^{27,28,29}, Freddie C. Hamdy^{30,31}, Jenny L. Donovan³², Ruth C. Travis³³, Robert J.
9 Hamilton^{34,35}, Sue Ann Ingles³⁶, Barry S. Rosenstein^{37,38}, Yong-Jie Lu³⁹, Graham G.
10 Giles^{40,41,42}, Ana Vega^{43,44,45}, Manolis Kogevinas^{46,47,48,49}, Kathryn L. Penney⁵⁰, Janet L.
11 Stanford^{51,52}, Cezary Cybulski⁵³, Børge G. Nordestgaard^{54,55}, Hermann Brenner^{56,57,58},
12 Christiane Maier⁵⁹, Jeri Kim⁶⁰, Manuel R. Teixeira^{61,62}, Susan L. Neuhausen⁶³, Kim De
13 Ruyck⁶⁴, Azad Razack⁶⁵, Lisa F. Newcomb^{51,66}, Davor Leskelä⁶⁷, Radka Kaneva⁶⁸,
14 Nawaid Usmani^{69,70}, Frank Claessens⁷¹, Paul A. Townsend⁷², Manuela Gago-
15 Dominguez^{73,74}, Monique J. Roobol⁷⁵, Kay-Tee Khaw⁷⁶, Lisa Cannon-Albright^{77,78},
16 Hardev Pandha⁷⁹, Stephen N. Thibodeau⁸⁰, Peter Kraft⁸¹, Elio Riboli⁸²

17

18 ¹Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of
19 Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los
20 Angeles, CA 90015, USA

21 ²Department of Population and Quantitative Health Sciences, Case Western Reserve
22 University, Cleveland, OH 44106-7219, USA

23 ³Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA.

24 ⁴Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
25 Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1
26 8RN, UK

27 ⁵The Institute of Cancer Research, London, SM2 5NG, UK

28 ⁶Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
29 Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK

30 ⁷University of Cambridge, Department of Clinical Neurosciences, Stroke Research
31 Group, R3, Box 83, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK

32 ⁸Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH,
33 Bethesda, Maryland, 20892, USA

34 ⁹Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171

- 1 77 Stockholm, Sweden
- 2 ¹⁰Behavioral and Epidemiology Research Group, Research Program, American Cancer
3 Society, 250 Williams Street, Atlanta, GA 30303, USA
- 4 ¹¹Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical
5 Innovation and School of Biomedical Sciences, Queensland University of Technology,
6 Brisbane QLD 4059, Australia
- 7 ¹²Translational Research Institute, Brisbane, Queensland 4102, Australia
- 8 ¹³Australian Prostate Cancer Research Centre-Qld, Queensland University of
9 Technology, Brisbane; Prostate Cancer Research Program, Monash University,
10 Melbourne; Dame Roma Mitchell Cancer Centre, University of Adelaide, Adelaide; Chris
11 O'Brien Lifehouse and
- 12 ¹⁴Translational Research Institute, Brisbane, Queensland, Australia
- 13 ¹⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm,
14 Sweden
- 15 ¹⁶Department of Applied Health Research, University College London, London, WC1E
16 7HB, UK
- 17 ¹⁷Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
18 Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK
- 19 ¹⁸Institute of Biomedicine, Kiinamylynkatu 10, FI-20014 University of Turku, Finland
- 20 ¹⁹Department of Medical Genetics, Genomics, Laboratory Division, Turku University
21 Hospital, PO Box 52, 20521 Turku, Finland
- 22 ²⁰Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska
23 Institutet, SE-171 77 Stockholm, Sweden
- 24 ²¹Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden
- 25 ²²Division of Cancer Sciences, University of Manchester, Manchester Academic Health
26 Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation
27 Trust, Manchester, M13 9PL UK
- 28 ²³Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA
29 02115, USA
- 30 ²⁴Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen
31 Boulevard 99, 8200 Aarhus N, Denmark
- 32 ²⁵Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N
- 33 ²⁶Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway
- 34 ²⁷Nuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6,

- 1 John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
- 2 ²⁸University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital,
3 Hills Road, Cambridge CB2 0QQ, UK
- 4 ²⁹Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge
5 UK
- 6 ³⁰Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX1 2JD, UK
- 7 ³¹Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK
- 8 ³²Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK
- 9 ³³Cancer Epidemiology Unit, Nuffield Department of Population Health, University of
10 Oxford, Oxford, OX3 7LF, UK
- 11 ³⁴Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto ON M5G 2M9,
12 Canada
- 13 ³⁵Dept. of Surgery (Urology), University of Toronto, Canada
- 14 ³⁶Department of Preventive Medicine, Keck School of Medicine, University of Southern
15 California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA
- 16 ³⁷Department of Radiation Oncology and Department of Genetics and Genomic
17 Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy
18 Place, New York, NY 10029, USA
- 19 ³⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
20 Sinai, New York, NY 10029-5674 , USA.
- 21 ³⁹Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of
22 London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK
- 23 ⁴⁰Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne,
24 VIC 3004, Australia
- 25 ⁴¹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global
26 Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia
- 27 ⁴²Precision Medicine, School of Clinical Sciences at Monash Health, Monash University,
28 Clayton, Victoria 3168, Australia
- 29 ⁴³Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, 15706,
30 Spain.
- 31 ⁴⁴Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De
32 Compostela, 15706, Spain.
- 33 ⁴⁵Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain
- 34 ⁴⁶ISGlobal, Barcelona, Spain

- 1 ⁴⁷IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- 2 ⁴⁸Universitat Pompeu Fabra (UPF), Barcelona, Spain
- 3 ⁴⁹CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- 4 ⁵⁰Channing Division of Network Medicine, Department of Medicine, Brigham and
5 Women's Hospital/Harvard Medical School, Boston, MA 02184, USA
- 6 ⁵¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle,
7 Washington, 98109-1024, USA
- 8 ⁵²Department of Epidemiology, School of Public Health, University of Washington,
9 Seattle, Washington 98195, USA
- 10 ⁵³International Hereditary Cancer Center, Department of Genetics and Pathology,
11 Pomeranian Medical University, Szczecin, Poland
- 12 ⁵⁴Faculty of Health and Medical Sciences, University of Copenhagen, 2200
13 Copenhagen, Denmark
- 14 ⁵⁵Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
15 University Hospital, Herlev, 2200 Copenhagen, Denmark
- 16 ⁵⁶Division of Clinical Epidemiology and Aging Research, German Cancer Research
17 Center (DKFZ), D-69120, Heidelberg, Germany
- 18 ⁵⁷German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-
19 69120 Heidelberg, Germany
- 20 ⁵⁸Division of Preventive Oncology, German Cancer Research Center (DKFZ) and
21 National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460
22 69120 Heidelberg, Germany
- 23 ⁵⁹Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany
- 24 ⁶⁰The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary
25 Medical Oncology, 1515 Holcombe Blvd., Houston, TX 77030, USA
- 26 ⁶¹Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), Porto,
27 Portugal
- 28 ⁶²Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal
- 29 ⁶³Department of Population Sciences, Beckman Research Institute of the City of Hope,
30 1500 East Duarte Road, Duarte, CA 91010, 626-256-HOPE (4673)
- 31 ⁶⁴Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences,
32 Proeftuinstraat 86, B-9000 Gent
- 33 ⁶⁵Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala
34 Lumpur, Malaysia

1 ⁶⁶Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510,
2 Seattle, WA 98195, USA

3 ⁶⁷Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246
4 Hamburg, Germany

5 ⁶⁸Molecular Medicine Center, Department of Medical Chemistry and Biochemistry,
6 Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria

7 ⁶⁹Department of Oncology, Cross Cancer Institute, University of Alberta, 11560
8 University Avenue, Edmonton, Alberta, Canada T6G 1Z2

9 ⁷⁰Division of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue,
10 Edmonton, Alberta, Canada T6G 1Z2

11 ⁷¹Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine,
12 KU Leuven, BE-3000, Belgium

13 ⁷²Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology,
14 Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester
15 Biomedical Research Centre, Health Innovation Manchester, Univeristy of Manchester,
16 M13 9WL

17 ⁷³Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de
18 Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario
19 Universitario de Santiago, Servicio Galego de Saúde, SERGAS, 15706, Santiago de
20 Compostela, Spai

21 ⁷⁴University of California San Diego, Moores Cancer Center, La Jolla, CA 92037, USA

22 ⁷⁵Department of Urology, Erasmus University Medical Center, 3015 CE Rotterdam, The
23 Netherlands

24 ⁷⁶Clinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK

25 ⁷⁷Division of Epidemiology, Department of Internal Medicine, University of Utah School
26 of Medicine, Salt Lake City, Utah, USA

27 ⁷⁸George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City,
28 Utah 84148, USA

29 ⁷⁹The University of Surrey, Guildford, Surrey, GU2 7XH

30 ⁸⁰Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
31 55905, USA


32 ⁸¹Program in Genetic Epidemiology and Statistical Genetics, Department of
33 Epidemiology, Harvard School of Public Health, Boston, MA, USA

34 ⁸²Department of Epidemiology and Biostatistics, School of Public Health, Imperial

1 College London, SW7 2AZ, UK

2

3



1

2

1

2 **Table S1. Contributing studies.** Descriptions of PRACTICAL study groups that
 3 contributed data towards this analysis. The number of cases and controls provided by
 4 each study group is also listed.

Study Group	Study Group Name	Cases	Controls
Acronym			
BioVU	Vanderbilt University	204	0
CPDR	Uniformed Services University-Center for Prostate Disease Research	135	41
CeRePP	French Prostate Case-Control Study	101	84
EPICAP	EPIdemiology of Prostate CAncer	20	9
KARUPROSTATE	French West Indies Prostate cancer Study	363	386
MIAMI-WFPCS	The University of Miami – Sylvester Comprehensive Cancer Center	59	49
MOFFITT	The Moffitt Group	101	91
NMHS	Nashville Men’s Health Study	176	188
PCaP	North Carolina – Louisiana Prostate Cancer Project Consortium	967	0
PROtEuS	Prostate Cancer and Environment Study	70	53
SABOR	San Antonio Center of Biomarkers of Risk for Prostate Cancer	105	106
SCCS	Southern Community Cohort Study	291	1498
SCPCS	South Carolina Prostate Cancer Study	57	32
SFPCS	San Francisco Bay Area Prostate Cancer Study	81	36
SWOG-PCPT	Prostate Cancer Prevention Trial	43	121
SWOG-SELECT	Selenium and Vitamin E Cancer Prevention Trial	30	167
UKGPCS	U.K. Genetic Prostate Cancer Study and The Prostate Cancer Research Foundation Study	365	0
WUGS	Washington University Genetics Study	72	152

5

6

1 **Table S2. Permutation performance.** Mean and 95% confidence intervals for
2 performance metrics estimated for each permutation of the cross-validation procedure.

metric	Any prostate cancer	Aggressive prostate cancer
HR20/50	0.53 [0.51-0.54]	0.51 [0.50-0.53]
HR80/20	4.07 [3.81-4.32]	4.42 [4.09-4.77]
HR98/50	3.49 [3.29-3.69]	3.77 [3.50-4.04]

3

4

1 **Table S3. Results of SNP-scan.** Description of 12 SNPs identified in 100 permutations
2 of cross-validation SNP-scan. The position of each SNP is based on version 37. The
3 count is the number of times the SNP appeared in permutations.

RS number	Chromosome	Effect	Reference	Position	count
rs76229939	8	G	A	128085394	87
rs74421890	8	A	G	128096183	87
rs5013678	8	G	A	128103979	54
rs144732329	2	C	A	20130787	18
rs76595456	8	A	G	128087829	13
rs339353	6	A	C	117202475	8
rs1456315	8	A	G	128103937	6
rs184167671	17	G	A	54159621	5
rs339359	6	A	G	117160693	3
rs610424	6	G	A	117212258	1
rs339302	6	T	A	117224641	1
rs6983561	8	C	A	128106880	1

4

5

- 1 **Table S4. SNP correlation matrix.** Pearson correlation coefficient matrix of three SNPs
- 2 selected for addition to the PHS46+African model.

RS number	rs76229939	rs74421890	rs5013678
rs76229939	1		
rs74421890	-0.0520	1	
rs5013678	-0.0646	-0.0759	1

3

4

1 **Table S5. Reference Threshold PHS46+African scores.** Reference threshold values
2 for PHS46+African scores in African dataset.

3

Threshold	Value
20 th percentile	-0.58
30 th percentile	-0.47
70 th percentile	-0.13
80 th percentile	-0.02
98 th percentile	0.39

4

5

6

1 **Table S6. Mean PHS46+African scores.** Mean PHS46+African risk scores are
2 tabulated for all individuals, cases, and controls in the African dataset.

3

	Mean [95% CI]
All	-0.22 [-0.23,-0.21]
Cases	-0.16[-0.17,-0.14]
Controls	-0.29[-0.30,-0.28]

4

5